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Psychedelic Psychiatry
Abstract
We are amidst a 'Renaissance' in the field of psychedelic psychiatry. For several decades, following a
period of promising research, governmental barriers and regulations halted any research into the utility of
these substances in psychiatry. Over the past few decades, however, we are seeing a revival of these
studies due to an abundance of positive findings as well as the need for improved psychiatric treatments.
Studies have established substances such as psilocybin and LSD to be effective in treating depressive
disorders, sometimes even more so than current 'gold standards'. MDMA is being recognized as a
powerful tool, in conjunction with psychotherapy, for addressing PTSD symptomatology. This paper will
provide a brief history of the use of psychedelics in psychiatry and discuss some of the most important
recent research findings.
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Psychedelic Psychiatry
Neil Harjai
Rochester Regional Health, USA

Abstract
We are amidst a ‘Renaissance’ in the ﬁeld of psychedelic psychiatry. For several decades, following a period of
promising research, governmental barriers and regulations halted any research into the utility of these substances in
psychiatry. Over the past few decades, however, we are seeing a revival of these studies due to an abundance of positive
ﬁndings as well as the need for improved psychiatric treatments. Studies have established substances such as psilocybin
and LSD to be effective in treating depressive disorders, sometimes even more so than current ‘gold standards'. MDMA
is being recognized as a powerful tool, in conjunction with psychotherapy, for addressing PTSD symptomatology. This
paper will provide a brief history of the use of psychedelics in psychiatry and discuss some of the most important recent
research ﬁndings.
Keywords: Psychedelics, Psychiatry, lsd, Mescaline, Psilocybin

1. Introduction
he term ‘psychedelics’ oftentimes evokes images of long-haired, war-protesting ‘hippies’
or stories of individuals believing that they can ﬂy off
of buildings. It is true that their recreational use was
popularized in the 50s and 60s during the counterculture movement and that one can ﬁnd stories of
psychedelic users making poor decisions. But, these
are very narrow and rigid depictions of these substances that are largely borne of government-led
pursuits to quash protests and subsequent negatively-biased media coverage.1 Despite these barriers,
we are starting to see what some refer to as a ‘Renaissance’2 in the study of psychedelics, particularly
in the ﬁeld of psychiatry. A deeper look at psychedelic
substances' histories, stigmas, and roles in improving
the state of psychiatric treatment is necessary to
evolve the overall public's stance on these tools.

T

2. History
Substances such as psilocybin (psychoactive
compound in ‘magic mushrooms’), mescaline (psychoactive compound in the cactus, peyote), and
DMT (psychoactive compound in the vine

Banisteriopsis caapi) have been used for hundreds
and thousands of years, usually in ritualistic contexts.2,3 Groups such as the Mayans, Aztecs, and
Olmec are often cited as utilizing these substances.2
Many groups in Mesoamerica continue these traditions. More recently, in the West, psychedelics
have been of interest due to their potential use in
studying and treating mental illnesses. German
psychiatrist, Emil Kraepelin, used psychedelics to
‘experimentally induce psychoses’.3 Substances
such as mescaline were studied in the early 1900s
due to interest in their ability to induce psychoticlike states as well as derealization and depersonalization.3 However, modern psychedelic science
really began to progress following Albert Hoffman's
discovery of LSD in 1943.4 He was a Swiss chemist
working on developing cardiovascular drugs at
Sandoz Pharmaceuticals. Following his accidental
ingestion of LSD and his reported experience, there
was a desire to further study LSD and similar substances due to the possibility that they could produce mental effects similar to those seen in
psychiatric disorders. Hence the term ‘psychomimetics’.3 A large number of initial studies using
psychedelics were focused on alcoholism and other
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types of addictions as well as mental status at the
end-of-life.5 These studies led to a greater understanding of serotonergic pharmacology, directly
contributing to the development of many modern
antidepressants.6 Unfortunately, these studies came
to a rather abrupt halt during the 1960s. While these
substances were showing results of value in clinical
studies, they became mainstream and were associated with social unrest and the anti-Vietnam counterculture movement.1 Sandoz Pharmaceuticals
ended their distribution of LSD and psilocybin due
to “unforeseen public reaction”.3 The FDA stopped
approving new studies involving the use of psychedelics but did allow ongoing ones to continue.
Prior to banning psychedelic studies, the NIH had
funded over 130 studies involving LSD and other
substances, many with positive results.5 The last
study ended in 1976 and it was not until 1994 that
another study, involving DMT, was started. Around
the late 1990s, neuroimaging techniques such as
PET studies began to be used to characterize the
effects psychedelics had in the brain.3,7 In the early
2000s, a group of researchers at Johns Hopkins
became some of the ﬁrst to obtain regulatory
approval to reinitiate psychedelic research in psychedelic-naive patients. This was the start of the
Johns Hopkins Center for Psychedelic and Consciousness Research, which has continued to play a
major role in progressing this area of research.8
Their 2006 study of the potential therapeutic value
of a psychedelic substance marked a major milestone. This one involved the use of psilocybin in
patients with OCD. While they reported marked
decreases in symptoms, the group was too small for
the results to be considered conclusive.3 Since then,
we have seen an increase in interest and studies into
this group of chemicals, particularly in the realm of
depression, anxiety, and cancer-related mental
health issues.

3. Current status
Currently, a search on clinicaltrials.gov for studies
on psychedelic substances including LSD, psilocybin, MDMA, or mescaline will yield over 200 active
or soon-to-be active projects.9 Many of these studies
are focused on depression, addiction, and PTSD.
Trials involving psychedelics have become relatively standardized, involving four phases: assessment, preparation, experience, and integration.5 In
the assessment phase, patients are evaluated to
determine whether they are mentally and physically
suitable for psychedelic therapy. Most trials will
exclude patients with personal or family histories of
psychoses or bipolar disorders, however this may
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not be the case for long. Patients are often required
to have been off of antidepressants and other psychotropic medications due to their potential interactions with one of the primary targets of
psychedelic substances, the 5HT2A receptor. In the
preparation stage, patients are presented with an
overview of the nature and dynamics of psychedelics, usually a day or two before administration.
The potential challenges one may encounter during
the experience are discussed at this time as well.
The experience itself typically lasts four to 5 h
depending on the substance and mode of administration. Patients are given eyeshades and a preapproved music playlist. A trained guide is present
with the patient throughout the experience to reassure them they are being watched over. In some
cases, verbal engagement does occur, but this is not
always necessary. During the integration phase, the
professional guide talks about the experience with
the patient and helps them make sense of it.
Oftentimes, additional talk-therapy sessions follow
the experience.

4. Mechanisms of action
The ways in which psychedelic substances exert
their therapeutic effects have not been fully elucidated. However, there are some major targets that
have been identiﬁed. Psychedelics primarily exert
their inﬂuence via 5HT2A receptor agonism at pyramidal neurons in the prefrontal cortex.7 This action
underlies
the
hallucinogenic
effects
characteristic of these substances. Other serotonergic receptors such as 1 A, 2C, 4, 5, 6, and 7, as
well as dopaminergic and alpha adrenergic receptors have also been implicated. Interactions with
these receptors is thought to increase prefrontal
cortical activity, resulting in increases in the rates of
5HT and DA neuronal ﬁrings. This is supported by
PET trials showing increased striatal dopamine
levels following administration of psilocybin and
LSD.11 It is thought that psychedelic substances
induce neuroplastic adaptations, such as downregulation of cortical 5HT2A receptors. In studies on
antidepressants, downregulation of these receptors
is a correlate of chronic effective treatment.12
Serotonergic modulation is also associated with
increases in some neurotrophic factors such as
brain-derived neurotrophic factor, BDNF, involved
in neuroplasticity.7,10 Suppressed levels of BDNF
due to polymorphisms (particularly Val66Met) and/
or chronic stress are highly associated with major
depressive disorder. Studies on antidepressant
treatments have shown SSRIs to promote BDNF
expression.13 It is, however, unclear whether BDNF
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is involved in modulating the effects of antidepressant/psychedelic treatment or if it is a progression/
etiological factor.
Serotonergic psychedelics exert other inﬂuences
through anti-inﬂammatory effects. Speciﬁcally, we
see suppression of TNF- after administration.7 This,
and other inﬂammatory markers such as IL-6 and
IL-1b, are associated with addiction and mood
disorders.14
Neuroplasticity is another potential mechanism
by which psychedelics may promote a healthier
mental well-being. In vivo and in vitro experiments
have shown serotonergic psychedelics to increase
neuritogenesis, spinogenesis, and synaptogenesis.15
This occurs via activation of tropomyosin receptor
kinase B (TrkB), mammalian target of rapamycin
(mTOR), as well as 5HT2A signaling pathways. It
has been shown that low-dose psilocybin increases
hippocampal neurogenesis, although high-dose
administration may actually decrease this process.
Decreased neuroplasticity is implicated in psychiatric disorders. It is thought that chronic stress leads
to excessive glutamate release which contributes to
neuronal atrophy/connectivity and decreased hippocampal neurogenesis.16 We have seen that antidepressants can reverse this to some extent.17

5. Safety
Some of the most common arguments against the
use of psychedelic substances in any manner, especially a therapeutic one, have to do with safety. Fears
regarding harmful, irreversible physiological effects
or risks of addiction fuel these arguments. However,
these are largely unfounded and likely stem from
unfamiliarity with the substances and the research
into them. There is no doubt that these substances
induce a vulnerable psychological state in patients. But,
this vulnerable state may actually underlie the ability
of the substances to exert their therapeutic effects.
Sometimes, when taken with other substances, in
unfamiliar surroundings, or with individuals unknown to the user, a state of intense anxiety and
paranoia can ensue. This is what is referred to as a
‘bad trip’. To safeguard against this, there are strict
protocols, as mentioned above, as to who may
participate in these trials. Additionally, professionals
are used to provide educational sessions, to be there
with the participant throughout the experience, and to
help them make sense of it afterwards.
Physiologically, the effects of psychedelics are
quite mild. Although MDMA has been shown to be
neurotoxic at high doses, there is no evidence that
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classical psychedelics such as LSD, psilocybin, and
mescaline carry this risk.18 The most common
physiological effects include dilated pupils and
moderately elevated pulse and blood pressure.19
These effects are relatively modest and are rarely
enough to cause distress in patients to the point that
they cannot continue.20 In terms of abuse and
addiction, psychedelics do not impose much of a
risk. They are not typically considered drugs of
dependence as they are not reinforcing.21 This is
consistent with observations that these substances
are not reliably self-administered in nonhuman
animal studies.22

6. Why it matters
Psychiatric disorders are pervasive throughout the
world. They do not discriminate based on gender,
race, or social class. Although we do see higher rates
of more severe psychiatric illness in poorer communities, and in people of color, this is largely due
to lack of adequate access to care.23 This lack of
access is multifactorial and includes the stigma
associated with having a psychiatric illness as well
as the long-held belief that one ought to be able to
‘shake it off’. Depression is a particularly major
public health problem associated with huge burdens. Major depressive disorder affects more than
300 million people worldwide and is the number
one cause of disability, according to the WHO.23 The
relative risk of all-cause-mortality for those with
depression is 1.7 times greater than the general
public.23 It is estimated that the yearly economic
burden of depression is $210B.23 While antidepressants have presented a life-saving solution for
many, even the best ones show modest efﬁcacy and
come with non-negligible side effects and high
relapse rates. They often take four to six weeks to
have an effect, a luxury not all can afford. Additionally, the efﬁcacy of psychiatric medications are
severely limited to due patient adherence issues.
Psychedelics can achieve clinically signiﬁcant results in much shorter periods of time with fewer
doses. For PTSD, the ﬁrst line of therapeutics involves the antidepressants sertraline and paroxetine. 40e60% of patients with PTSD do not respond
to these treatments.10 Additionally, although
different types of psychotherapy are the gold standard for PTSD and other conditions, many will still
fail to respond. This highlights the need for additional modes of treatments with greater efﬁcacies,
rapid onset, and those that need not rely on strict
adherence.

3

Advances in Clinical Medical Research and Healthcare Delivery, Vol. 2 [2022], Iss. 2, Art. 12

7. Study #1: Increased global integration in the
brain after psilocybin therapy for depression
Daws, R.E., Timmermann, C., Giribaldi, B. et al.
Increased global integration in the brain after psilocybin therapy for depression. Nat Med 28, 844e851
(2022). https://doi.org/10.1038/s41591-022-01744-z.
7.1. Question
Does psilocybin offer antidepressant effects and, if
so, how does its mechanism compare to those of
traditional antidepressants, such as escitalopram?
7.1.1. Level of Evidence
Open-label trial - III.
Double-Blind Randomized Controlled Trial - II.
7.2. Methods
7.2.1. Open-label trial
19 participants with treatment-resistant depression were enrolled. Three individuals were excluded
due to excessive head fMRI head motion. Baseline
clinical assessments, the Beck Depression Inventory
(emphasizes the cognitive features of depression)
and resting state fMRI, were obtained. fMRI data
was used to compare baseline and post-treatment
brain network modularity. Participants received a
‘low’ 10 mg psilocybin dose and a ‘high’ 25 mg dose
separated by one week. One day later, a second set
of clinical assessments and fMRIs were obtained.
Pearson correlations between post-treatment brain
modularity and BDI scores were calculated at one
week, three months, and six months.
7.2.2. Double-Blind Randomized Controlled Trial
59 participants with major depressive disorder
were recruited. 16 were excluded due to excessive
head fMRI motion, adverse effects to escitalopram,
COVID lockdown, or for not taking the daily placebo capsules. Baseline clinical assessments, BDI
and others, and resting state fMRI were obtained.
The psilocybin arm received a 25 mg dose of psilocybin on dose day 1 (DD1), followed by three weeks
of daily placebo (cellulose) capsules. Following the
three weeks, they were dosed again with 25 mg
psilocybin on DD2 followed by another three weeks
of daily placebo capsules. The escitalopram received
an inert 1 mg psilocybin dose on DD1, followed by
three weeks of 10 mg escitalopram. They then
received another inert 1 mg psilocybin dose on DD2
followed by three weeks of 20 mg escitalopram.
After this, both arms were re-assessed and had
repeat fMRIs.
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7.3. Results
7.3.1. Open-label trial
Rapid, substantial, and sustained reductions in
depression severity (BDI score) were seen after
treatment. The baseline BDI score was 34.81. At
week one, the change was 21 points, p < 0.001,
d ¼ 1.78. At six months, this remained signiﬁcant
with a change from baseline of 14.19 points,
p < 0.001, d ¼ 1.07. Additionally, brain network
modularity was signiﬁcantly reduced just one day
following treatment with a mean difference of 0.29
(p ¼ 0.012, d ¼ 0.72). Correlations between brain
modularity and BDI scores were not signiﬁcant at
one week and three months, but were signiﬁcant at
six months. Signiﬁcant reductions in the default
mode network, DMN, recruitment were observed
(mean difference 0.54, p ¼ 0.009, d ¼ 0.75). Additionally, they observed an increased betweennetwork integration between the DMN and the executive network, EN (mean difference 0.53, p ¼ 0.01,
d ¼ 0.75), and between the DMN and salience
network, SN (mean difference 0.55, p ¼ 0.01,
d ¼ 0.72).
7.3.2. Double-Blind Randomized Controlled Trial
The reductions in BDI-measured depression
severity were signiﬁcantly greater in the psilocybin
arm at two, four, and six weeks. Pairwise comparisons relative to baseline was 8.73 (p ¼ 0.002,
d ¼ 0.98) at two weeks, 7.79 (p ¼ 0.013, d ¼ 0.77) at
four weeks, and 8.78 (p ¼ 0.013, d ¼ 0.75) at six
weeks. Brain network modularity was signiﬁcantly
reduced in the psilocybin arm at three weeks with a
mean difference of 0.39 (p ¼ 0.039, d ¼ 0.47)
compared to no signiﬁcant change in the escitalopram arm. These decreases in brain modularity in
the psilocybin arm were correlated with improvement in depression symptom severity (r ¼ 0.42,
p ¼ 0.025, one-tailed). Changes in network ﬂexibility
were correlated with changes in BDI score. Specifically increased dynamic ﬂexibility among the EN
and SN were strongly correlated with symptom
improvement at six weeks. There were no signiﬁcant correlations between changes in BDI scores and
changes in dynamic ﬂexibility in the escitalopram
arm.
7.4. Conclusions
7.4.1. Open-label trial
The DMN is a hierarchically supraordinate
intrinsic brain network associated with introspection and self-referential thinking which is often
overactive in depression. Other higher-order brain
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networks like the EN and SN have also been
implicated in depression. The EN and SN are
associated with tasks requiring cognitive ﬂexibility
like learning and task switching. The reduction in
overall brain network modularity seen at day one
implies a global increase in functional connectivity
between the brain's main intrinsic networks. Additionally, it suggests that these decreases in modularity are related to the long-term improvements in
depression severity at six months.
7.4.2. Double-Blind Randomized Controlled Trial
Psilocybin provided a greater amount of depressive symptom relief compared with escitalopram at
this trial's end points. Unlike escitalopram, psilocybin treatment resulted in increased global brain
network integration, strongly associated with the
improvement in depressive symptoms. Dynamic
ﬂexibility, a term used to describe the rate at which
brain regions change their community allegiance
during any given time, was signiﬁcantly increased
in the psilocybin arm, suggesting that its antidepressant effects are related to its ability to increase
connectivity between brain regions.
Taken together, this paper supports the notion of
psilocybin having antidepressant effects. It goes
further and describes the unique way in which it is
able to improve depressive symptoms. Depression,
and other psychiatric conditions, is marked by
increased brain modularity or within-network connectivity and a lack of inter-network connectivity.
This correlates with the ruminative, constricted
symptoms in depression. Psilocybin increases global
brain integration, allowing the brain to visit a
broader state space with increased communications
between regions ordinarily out of community limits.
Speciﬁcally, we see major changes in the DMN, EN,
and SN, the areas housing the highest-density of
5HT2A receptors.
7.5. Limitations
The effects of fMRI head motion cannot be totally
ruled out. Additionally, it would be helpful to collect
a larger number of fMRI data as the dynamic analyses are difﬁcult to do.
7.6. Bottom-line
Psilocybin exerts antidepressant effects likely due
to an increase in inter-network connectivity, allowing the brain to break harmful and repetitive
thought patterns.
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8. Study #2: MDMA-assisted therapy for
severe PTSD, a randomized, double-blind,
placebo-controlled phase 3 study
Mitchell, J.M., Bogenschutz, M., Lilienstein, A.
et al. MDMA-assisted therapy for severe PTSD: a
randomized,
double-blind,
placebo-controlled
phase 3 study. Nat Med 27, 1025e1033 (2021). https://
doi.org/10.1038/s41591-021-01336-3.
8.1. Question
Can MDMA alleviate the symptomatology of
PTSD when used in conjunction with manualized
therapy?
Level of Evidence: II.
8.2. Methods
Studies were done in the US, Canada, and Israel.
99 participants were ultimately included. Patients
were diagnosed with severe PTSD, with a mean
duration of 14.8 years. 19 of the participants had the
dissociate subtype. Patients were required to go
through a psychiatric medication washout. The
Clinician-Administered PTSD Scale for DSM-5
(CAPS-5) was used to evaluate PTSD symptoms.
The Sheehan Disability Scale, SDS, was used to
measure functional impairment. The Beck Depression Inventory scale was used to evaluate depressive
symptoms. Suicidality was assessed using the
Columbia Suicide Severity Rating Scale, C-SSRS.
Patients were randomized to an MDMA arm and a
placebo arm. Baseline CAPS-5 and SDS scores were
obtained. Over 18 weeks, participants underwent
three preparatory sessions, three experimental sessions, nine integration sessions, and four endpoint
assessments. Clinical assessments were completed
again following each experimental session.
8.3. Results
MDMA signiﬁcantly reduced PTSD symptomatology with a mean change in CAPS-5 score between baseline and 18 weeks of 24.4 in the MDMA
group versus 13.9 in the placebo group (p < 0.0001,
d ¼ 0.91). The MDMA group showed a decrease in
SDS score of 3.1 vs 2.0 in the placebo group
(p ¼ 0.0116, d ¼ 0.43). The effects seen within the
MDMA group were equal among participants with
comorbidities often associated with treatment
resistance - alcohol use disorder, substance use
disorder, trauma, etc. The MDMA group showed a
greater reduction in depressive symptoms as seen
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with a mean change of BDI score of 19.7 versus
10.8 in the placebo group (p ¼ 0.0026, d ¼ 0.67). At
the end of the 18 weeks, 67% of participants in the
MDMA group no longer met criteria for PTSD,
compared to 32% in the placebo group. 33% of
the MDMA group met the criteria for remission
versus 5% in the placebo group. Suicidality within
the placebo and MDMA groups were similar at
baseline and did not exceed baseline throughout the
study.
8.4. Conclusions
MDMA administration, alongside manualized
therapy, showed a greater degree of relief from
PTSD symptomatology compared to manualized
therapy alone. The effect size of the difference in
reduction of symptomatology between the two
groups, d ¼ 0.91, is one of the highest seen among
other PTSD pharmacotherapy, suggesting a very
strong relationship between MDMA and relief of
symptoms. This is compared to the effect sizes seen
in comparisons between the ﬁrst-line PTSD pharmacotherapies sertraline and paroxetine versus
placebo, 0.31e0.37 and 0.45e0.56, respectively.
PTSD is strongly associated with excessive amygdala activity in response to fearful images/situations. The amygdala is also a site of extensive
serotonergic innervation. It may be that MDMA
exerts its therapeutic effect of regulating fear-based
behavior by modulating serotonergic activity at this
site, thus facilitating the processing and release of
fear-related memories.
8.5. Limitations
The population was relatively homogenous in
terms of race and ethnicity. The sample size was
smaller than hoped for due to COVID lockdowns.
8.6. Bottom-line
MDMA, when used in conjunction with manualized therapy, produces signiﬁcantly greater relief
from PTSD symptomatology compared to manualized therapy alone.

9. Study #3: Effects of Psilocybin-assisted
therapy on MDD
Davis AK, Barrett FS, May DG et al. Effects of
Psilocybin-Assisted Therapy on Major Depressive
Disorder: A Randomized Clinical Trial. JAMA Psychiatry.
2021;
78(5):481e489.
doi:10.1001/
jamapsychiatry.2020.3285.

https://scholar.rochesterregional.org/advances/vol2/iss2/12
DOI: 10.53785/2769-2779.1108

9.1. Question
Is psilocybin effective in reducing depressive
symptomatology in those with moderate or severe
major depressive disorder?
Level of Evidence: II.
9.2. Methods
Patients aged 21e75 with moderate to severe
depression were identiﬁed. 27 participants were
eligible and ultimately included. Patients could not
have been actively using antidepressants (at least
ﬁve half-lives before screening and four months
after enrollment). Other exclusionary criteria
included moderate to severe alcohol use disorder,
personal or family history of psychosis, serious
suicide attempts, and psychiatric hospitalizations.
The primary outcome measure was the GRIDHAMD, a modiﬁed form of the Hamilton Depression Rating Scale. Secondary measure outcomes
included depressive symptoms assessed by the Beck
Depression Inventory, BDI, and the 9-item Patient
Health Questionnaire, PHQ9. Anxiety symptoms
were assessed using the Hamilton Anxiety Rating
Scale. The trial was divided into an immediate
treatment condition group and a delayed treatment
condition group. The immediate treatment group
lasted eight weeks and involved at least 18 in-person
visits, including two psilocybin administration sessions. A dose of 20 mg/70 kg was used on dose day 1
(DD1) and 30 mg/70 kg was used on DD2. Dose days
were separated by 1.6 weeks. Participants underwent the experimental sessions around weeks three
and four and then had repeat assessments on weeks
ﬁve and eight. In the delayed treatment group,
repeat assessments were completed on weeks ﬁve
and eight. They then received the exact same
treatment as the immediate treatment group with
dose days occurring around weeks 11 and 12 and
repeat assessments on weeks 13 and 16.
9.3. Results
Authors observed signiﬁcantly lower depression
scores at weeks one and four in the immediate
treatment group compared with the delayed group.
Compared to baseline, the mean change in GRIDHAMD scores among the immediate treatment
group was 14.9 at week ﬁve and 14.4 at week
eight. In the delayed treatment group, mean
changes in score were þ1.3 at week ﬁve and
þ1.1 at week eight. These differences were statistically signiﬁcant at week ﬁve (p < 0.001, d ¼ 2.5) and
at week eight (p < 0.001, d ¼ 2.6). 71% of participants
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in the immediate treatment group had a clinically
signiﬁcant response to the intervention, deﬁned as
50% or greater reduction in GRID-HAMD scores, at
weeks ﬁve and eight. 58% met criteria for remission,
a score of seven or less, at week ﬁve and 54% at
week eight.

which is gaining in interest and importance in the
medical landscape. While current treatments can
certainly be life-saving for many, there is room to
improve. Psychedelic substances are one of the most
powerful, yet under-studied, tools in our belt and
may represent a major component in the evolution
of psychiatry.

9.4. Conclusions

Conﬂict of interest
Psilocybin administered in the context of psychotherapy was able to produce rapid and sustained
antidepressant effects in those with moderate to
severe major depressive disorder with just two administrations. The rapidity with which these effects
were attained parallels that of ketamine. However,
some important differences include the longer lasting effects seen with psilocybin as well as its lower
potential for addiction and adverse events. These
qualities directly address the weaknesses of current
antidepressant treatments - time to effect, need for
strict adherence, and side effect proﬁle.
9.5. Limitations
This study employed a rather short-term follow
up. Like other studies mentioned, this sample was
largely homogenous, consisting of mainly white,
non-hispanics. The participants in this study had
relatively low risks of suicide and had moderate to
severe depression. These results could be different
in more acutely-suicidal patients with a higher
severity depression.
9.6. Bottom-line
Psilocybin is capable of achieving quick, substantial, and sustained relief from depressive symptoms
when used in conjunction with psychotherapy
without the side effect proﬁle and need for adherence seen in modern antidepressant treatments.

10. Moving forward
As previously mentioned, there are hundreds of
active or soon-to-be active studies on the use of
psychedelic substances in the ﬁeld of psychiatry.
Undeniable evidence has created a path by which
these substances can actually be studied in standardized settings. There still, however, remains a
stigma associated with psychedelics. With the initiation of larger randomized control studies and a
fact-based approach to educating professionals and
the public about the substances’ mechanisms of
action, beneﬁts, and risks, hopefully the effects of
this stigma can be mitigated. Psychiatry is a ﬁeld
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